{"id":"dostarlimab-tsr-042","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Immune-mediated colitis"},{"rate":null,"effect":"Immune-mediated pneumonitis"},{"rate":null,"effect":"Immune-mediated hepatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dostarlimab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with its ligands (PD-L1 and PD-L2) on tumor cells and antigen-presenting cells. This blockade releases the 'brakes' on T-cell-mediated immunity, restoring anti-tumor immune responses. It is a humanized IgG4 monoclonal antibody designed to enhance durable anti-tumor immunity.","oneSentence":"Dostarlimab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:00.993Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Endometrial cancer, mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H)"},{"name":"Non-small cell lung cancer (in combination with chemotherapy)"},{"name":"Gastric or gastroesophageal junction cancer"}]},"trialDetails":[{"nctId":"NCT05870761","phase":"PHASE2","title":"Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Casey Cosgrove","startDate":"2023-10-17","conditions":"Recurrent Endometrial Serous Adenocarcinoma","enrollment":8},{"nctId":"NCT06567782","phase":"PHASE2","title":"A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-02-17","conditions":"Neoplasms, Colon","enrollment":120},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT04774419","phase":"PHASE2","title":"Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-02","conditions":"Endometrial Cancer","enrollment":62},{"nctId":"NCT05855200","phase":"PHASE3","title":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-08-01","conditions":"Colonic Neoplasms, Neoplasms, Colon","enrollment":892},{"nctId":"NCT04165772","phase":"PHASE2","title":"Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-12-11","conditions":"Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+)","enrollment":200},{"nctId":"NCT06238635","phase":"PHASE2","title":"Dostarlimab and Cobolimab in Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Meghan Shea","startDate":"2024-03-11","conditions":"Cervical Cancer, Advanced Cervical Carcinoma, Metastatic Cervical Cancer","enrollment":66},{"nctId":"NCT02715284","phase":"PHASE1","title":"Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2016-03-07","conditions":"Neoplasms","enrollment":730},{"nctId":"NCT04673448","phase":"PHASE1","title":"Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-10-18","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, BRCA-Associated Malignant Neoplasm","enrollment":18},{"nctId":"NCT05723562","phase":"PHASE2","title":"A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-04-03","conditions":"Neoplasms, Rectal","enrollment":154},{"nctId":"NCT03955978","phase":"PHASE1","title":"TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2019-10-15","conditions":"Endometrial Cancer, Cancer of the Endometrium","enrollment":10},{"nctId":"NCT03602859","phase":"PHASE3","title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2018-10-11","conditions":"Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma","enrollment":1400},{"nctId":"NCT03651206","phase":"PHASE2, PHASE3","title":"Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib","status":"RECRUITING","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2020-07-15","conditions":"Ovarian Carcinosarcoma, Endometrial Carcinosarcoma","enrollment":138},{"nctId":"NCT04701307","phase":"PHASE2","title":"Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-01","conditions":"Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":48},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT06640049","phase":"PHASE2","title":"A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-10-17","conditions":"Neoplasms, Rectal","enrollment":23},{"nctId":"NCT02817633","phase":"PHASE1","title":"A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2016-07-08","conditions":"Neoplasms","enrollment":463},{"nctId":"NCT04139902","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diwakar Davar","startDate":"2020-06-12","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":48},{"nctId":"NCT04837209","phase":"PHASE2","title":"Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-07-21","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":32},{"nctId":"NCT03981796","phase":"PHASE3","title":"A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2019-07-18","conditions":"Neoplasms","enrollment":785},{"nctId":"NCT04493060","phase":"PHASE2","title":"Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-12-28","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":22},{"nctId":"NCT04584255","phase":"PHASE2","title":"Niraparib + Dostarlimab In BRCA Mutated Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-12-18","conditions":"Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer","enrollment":62},{"nctId":"NCT03574779","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2018-11-15","conditions":"Ovarian Neoplasms","enrollment":77},{"nctId":"NCT05239546","phase":"PHASE2","title":"Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers","status":"RECRUITING","sponsor":"University of Iowa","startDate":"2023-03-24","conditions":"Colon Cancer, dMMR Colorectal Cancer","enrollment":25},{"nctId":"NCT03833479","phase":"PHASE2","title":"TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2019-06-28","conditions":"Cervical Cancer, Advanced Cancer","enrollment":134},{"nctId":"NCT05126342","phase":"PHASE2","title":"Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi","status":"WITHDRAWN","sponsor":"AGO Research GmbH","startDate":"2023-11-01","conditions":"Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":""},{"nctId":"NCT03680508","phase":"PHASE2","title":"TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Hawaii","startDate":"2019-12-19","conditions":"Adult Primary Liver Cancer, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer","enrollment":42},{"nctId":"NCT04313504","phase":"PHASE2","title":"Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Trisha Wise-Draper","startDate":"2020-11-04","conditions":"Head and Neck Cancer","enrollment":23},{"nctId":"NCT03250832","phase":"PHASE1","title":"Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-08-08","conditions":"Neoplasms","enrollment":111},{"nctId":"NCT04274023","phase":"PHASE2","title":"Study on TSR-042 in Advanced Clear Cell Sarcoma","status":"TERMINATED","sponsor":"Italian Sarcoma Group","startDate":"2024-01-29","conditions":"Sarcoma, Clear Cell","enrollment":3},{"nctId":"NCT03016338","phase":"PHASE2","title":"Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2017-11-06","conditions":"Endometrial Cancer","enrollment":51},{"nctId":"NCT03308942","phase":"PHASE2","title":"Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-09-29","conditions":"Neoplasms","enrollment":53},{"nctId":"NCT05751629","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2018-11-15","conditions":"Ovarian Neoplasm","enrollment":41},{"nctId":"NCT03955471","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer","status":"TERMINATED","sponsor":"Tesaro, Inc.","startDate":"2019-10-03","conditions":"Ovarian Neoplasms","enrollment":41},{"nctId":"NCT04895046","phase":"PHASE2","title":"Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma","status":"WITHDRAWN","sponsor":"Walid Shaib, MD","startDate":"2021-10-11","conditions":"HRD, Cholangiocarcinoma, Metastatic Cancer","enrollment":""},{"nctId":"NCT04679064","phase":"PHASE3","title":"Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-12-01","conditions":"Ovarian Cancer","enrollment":427},{"nctId":"NCT03806049","phase":"PHASE3","title":"Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","startDate":"2019-12","conditions":"Ovarian Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dostarlimab (TSR-042)","genericName":"Dostarlimab (TSR-042)","companyName":"Tesaro, Inc.","companyId":"tesaro-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dostarlimab (TSR-042) is a programmed cell death protein 1 antagonist, classified as an antibody. It is being studied in clinical trials for various indications, including rectal adenocarcinoma and advanced adult primary liver cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}